ID

35259

Descrizione

Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults; ODM derived from: https://clinicaltrials.gov/show/NCT02476617

collegamento

https://clinicaltrials.gov/show/NCT02476617

Keywords

versioni (1)
  1. 25/02/19 25/02/19 -
Titolare del copyright

See clinicaltrials.gov

Caricato su

25 febbraio 2019

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Chronic Hepatitis C NCT02476617

Inglese

Eligibility Chronic Hepatitis C NCT02476617

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. screening laboratory result indicating hcv gt1a infection.
Descrizione

Hepatitis C Genotype Laboratory test result

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0019196
UMLS CUI [1,2]
C0017431
UMLS CUI [1,3]
C0587081
2. chronic hcv infection.
Descrizione

Hepatitis C, Chronic

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0524910
3. subjects must be non-cirrhotic.
Descrizione

Study Subject Non-cirrhotic

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0681850
UMLS CUI [1,2]
C0439687
4. subjects must be treatment-naïve or have documentation that they were adherent to prior pegifn/rbv combination therapy and meet the criteria of prior pegifn/rbv treatment failure.
Descrizione

Therapy naive | PEGINTERFERON/RIBAVIRIN | PEGINTERFERON/RIBAVIRIN Treatment failure

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0919936
UMLS CUI [2]
C1875630
UMLS CUI [3,1]
C1875630
UMLS CUI [3,2]
C0162643
5. subjects must meet specific human leukocyte antigen (hla) allele requirements.
Descrizione

Human leukocyte antigen allele Specific

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0555907
UMLS CUI [1,2]
C0205369
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. women who are pregnant or breastfeeding.
Descrizione

Pregnancy | Breast Feeding

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
2. positive test result for hepatitis b surface antigen (hbsag) or anti-human immunodeficiency virus antibody (hiv ab) positive immunoassay.
Descrizione

Hepatitis B surface antigen positive Immunoassay | HIV antibody positive Immunoassay

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0149709
UMLS CUI [1,2]
C0020980
UMLS CUI [2,1]
C0920548
UMLS CUI [2,2]
C0020980
3. clinically significant abnormalities or co-morbidities, other than hcv infection, that make the subject unsuitable for this study or treatment.
Descrizione

Abnormality Study Subject Participation Status Inappropriate | Comorbidity Study Subject Participation Status Inappropriate | Exception Hepatitis C

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1704258
UMLS CUI [1,2]
C2348568
UMLS CUI [1,3]
C1548788
UMLS CUI [2,1]
C0009488
UMLS CUI [2,2]
C2348568
UMLS CUI [2,3]
C1548788
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0019196
4. current enrollment in another interventional clinical study, previous enrollment in this study, prior or current use of any investigational or commercially available anti-hcv agents other than pegifn or rbv (including previous exposure to abt-450, ombitasvir, or dasabuvir), or receipt of any investigational product within 6 weeks prior to study drug administration.
Descrizione

Study Subject Participation Status | Interventional Study | Anti-hepatitis C (HCV) Agents | Exception PEGINTERFERON | Exception Ribavirin | Exposure to ABT-450 | Exposure to Ombitasvir | Exposure to Dasabuvir | Investigational New Drugs

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C3274035
UMLS CUI [3]
C4324240
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0982327
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C0035525
UMLS CUI [6,1]
C0332157
UMLS CUI [6,2]
C3712108
UMLS CUI [7,1]
C0332157
UMLS CUI [7,2]
C3852670
UMLS CUI [8,1]
C0332157
UMLS CUI [8,2]
C3852512
UMLS CUI [9]
C0013230
5. history or solid organ transplant.
Descrizione

Solid organ transplant

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0730400
6. screening laboratory analysis that shows abnormal results.
Descrizione

Laboratory test result abnormal

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0438215
Ritorna all'inizio della pagina

Similar models

Eligibility Chronic Hepatitis C NCT02476617

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Hepatitis C Genotype Laboratory test result
Item
1. screening laboratory result indicating hcv gt1a infection.
boolean
C0019196 (UMLS CUI [1,1])
C0017431 (UMLS CUI [1,2])
C0587081 (UMLS CUI [1,3])
Hepatitis C, Chronic
Item
2. chronic hcv infection.
boolean
C0524910 (UMLS CUI [1])
Study Subject Non-cirrhotic
Item
3. subjects must be non-cirrhotic.
boolean
C0681850 (UMLS CUI [1,1])
C0439687 (UMLS CUI [1,2])
Therapy naive | PEGINTERFERON/RIBAVIRIN | PEGINTERFERON/RIBAVIRIN Treatment failure
Item
4. subjects must be treatment-naïve or have documentation that they were adherent to prior pegifn/rbv combination therapy and meet the criteria of prior pegifn/rbv treatment failure.
boolean
C0919936 (UMLS CUI [1])
C1875630 (UMLS CUI [2])
C1875630 (UMLS CUI [3,1])
C0162643 (UMLS CUI [3,2])
Human leukocyte antigen allele Specific
Item
5. subjects must meet specific human leukocyte antigen (hla) allele requirements.
boolean
C0555907 (UMLS CUI [1,1])
C0205369 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Pregnancy | Breast Feeding
Item
1. women who are pregnant or breastfeeding.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Hepatitis B surface antigen positive Immunoassay | HIV antibody positive Immunoassay
Item
2. positive test result for hepatitis b surface antigen (hbsag) or anti-human immunodeficiency virus antibody (hiv ab) positive immunoassay.
boolean
C0149709 (UMLS CUI [1,1])
C0020980 (UMLS CUI [1,2])
C0920548 (UMLS CUI [2,1])
C0020980 (UMLS CUI [2,2])
Abnormality Study Subject Participation Status Inappropriate | Comorbidity Study Subject Participation Status Inappropriate | Exception Hepatitis C
Item
3. clinically significant abnormalities or co-morbidities, other than hcv infection, that make the subject unsuitable for this study or treatment.
boolean
C1704258 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
C1548788 (UMLS CUI [1,3])
C0009488 (UMLS CUI [2,1])
C2348568 (UMLS CUI [2,2])
C1548788 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0019196 (UMLS CUI [3,2])
Study Subject Participation Status | Interventional Study | Anti-hepatitis C (HCV) Agents | Exception PEGINTERFERON | Exception Ribavirin | Exposure to ABT-450 | Exposure to Ombitasvir | Exposure to Dasabuvir | Investigational New Drugs
Item
4. current enrollment in another interventional clinical study, previous enrollment in this study, prior or current use of any investigational or commercially available anti-hcv agents other than pegifn or rbv (including previous exposure to abt-450, ombitasvir, or dasabuvir), or receipt of any investigational product within 6 weeks prior to study drug administration.
boolean
C2348568 (UMLS CUI [1])
C3274035 (UMLS CUI [2])
C4324240 (UMLS CUI [3])
C1705847 (UMLS CUI [4,1])
C0982327 (UMLS CUI [4,2])
C1705847 (UMLS CUI [5,1])
C0035525 (UMLS CUI [5,2])
C0332157 (UMLS CUI [6,1])
C3712108 (UMLS CUI [6,2])
C0332157 (UMLS CUI [7,1])
C3852670 (UMLS CUI [7,2])
C0332157 (UMLS CUI [8,1])
C3852512 (UMLS CUI [8,2])
C0013230 (UMLS CUI [9])
Solid organ transplant
Item
5. history or solid organ transplant.
boolean
C0730400 (UMLS CUI [1])
Laboratory test result abnormal
Item
6. screening laboratory analysis that shows abnormal results.
boolean
C0438215 (UMLS CUI [1])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial